Effects of zymogen and sellenium supplementation on Anti-tpoAb, T3,T4 and TSH serum levels, lipid profiles and quality of life in sub clinical hypothyriod patients

Comparing the effects of zymogen in combination with sellenium supplementation and placebo on Anti-tpoAb serum levels, T3,T4 and TSH serum levels, lipid profiles and quality of life in subclinical hypothyriod patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190212042686N2

Enrollment

Registered

2019-07-20

Start date

2019-06-24

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sub clinical hypothyriodism. Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention 1: The control group individuals will receive the placebo drug produced by Radin pharmaceutical company daily for 2 months. Intervention 2: The intervention group will receive 200 micro

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18-60 years sub clinical hypothyroidism involvement

Exclusion criteria

Exclusion criteria: Pregnancy Heart disease ( Ischemic heart disease, Congenital adrenal hyperplasia and valvular disease) liver Diseases proteinuria Renal failure Diseases

Design outcomes

Primary

Measure	Time frame
Tyroid Stimulating Hormune (TSH). Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Tyroid Peroxidase Anti Body (Anti TPO Ab). Timepoint: Baseline and 2 months after the treatment. Method of measurement: ??? ????????? ?????????.;Quality of Life. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: WHOQOL-BREF Questionnaire.;Free T4. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Triiodothyronine. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Triglycerides. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Total Cholesterol. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Low Density Lipoprotein-Cholesterol (LDL-C). Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;High Density Lipoprotein-Cholesterol (HDL-C). Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.	—

Measure

Time frame

Tyroid Stimulating Hormune (TSH). Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Tyroid Peroxidase Anti Body (Anti TPO Ab). Timepoint: Baseline and 2 months after the treatment. Method of measurement: ??? ????????? ?????????.;Quality of Life. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: WHOQOL-BREF Questionnaire.;Free T4. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Triiodothyronine. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Triglycerides. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Total Cholesterol. Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;Low Density Lipoprotein-Cholesterol (LDL-C). Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.;High Density Lipoprotein-Cholesterol (HDL-C). Timepoint: Baseline and 2 months after the Treatment. Method of measurement: Electrochemiluminescence Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Majid Mobasseri

Tabriz University of Medical Sciences

Mobasserimajid@yahoo.com+98 41 3335 7850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026